Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonists: A New Concept In CNS Disorders?
John Gatfield, Catherine Brisbare‐Roch, François Jenck, et al.
ChemMedChem (2010) Vol. 5, Iss. 8, pp. 1197-1214
Closed Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Chemistry and Biology Of Multicomponent Reactions
Alexander Dömlingꝉ, Wei Wang, Kan Wang
Chemical Reviews (2012) Vol. 112, Iss. 6, pp. 3083-3135
Open Access | Times Cited: 2255
Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Leslie Citrome
International Journal of Clinical Practice (2014) Vol. 68, Iss. 12, pp. 1429-1441
Open Access | Times Cited: 246
Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties
Paul J. Coleman, John D. Schreier, Christopher D. Cox, et al.
ChemMedChem (2012) Vol. 7, Iss. 3, pp. 415-424
Closed Access | Times Cited: 115
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 96
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, et al.
ChemMedChem (2013) Vol. 9, Iss. 2, pp. 311-322
Closed Access | Times Cited: 62
Association between Hypocretin-1 and Amyloid-β42 Cerebrospinal Fluid Levels in Alzheimer’s Disease and Healthy Controls
Diane Slats, Jurgen A.H.R. Claassen, Gert Jan Lammers, et al.
Current Alzheimer Research (2012) Vol. 9, Iss. 10, pp. 1119-1125
Closed Access | Times Cited: 62
Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
The present and future of synthetic orexin receptor agonists
Tsuyoshi Saitoh, Takeshi Sakurai
Peptides (2023) Vol. 167, pp. 171051-171051
Open Access | Times Cited: 13
The Hypocretin/Orexin System: Implications for Drug Reward and Relapse
Ainhoa Plaza‐Zabala, Rafaël Maldonado, Fernando Berrendero
Molecular Neurobiology (2012) Vol. 45, Iss. 3, pp. 424-439
Closed Access | Times Cited: 52
Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
Romano Di Fabio, Annalisa Pellacani, Stefania Faedo, et al.
Bioorganic & Medicinal Chemistry Letters (2011) Vol. 21, Iss. 18, pp. 5562-5567
Closed Access | Times Cited: 51
The potential role of the orexin reward system in future treatments for opioid drug abuse
Shahram Zarrabian, Esmail Riahi, Sara Karimi, et al.
Brain Research (2018) Vol. 1731, pp. 146028-146028
Closed Access | Times Cited: 39
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis
Alexander Heifetz, G. Benjamin Morris, Philip C. Biggin, et al.
Biochemistry (2012) Vol. 51, Iss. 15, pp. 3178-3197
Closed Access | Times Cited: 41
Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist
Christoph Boss, Catherine Roch‐Brisbare, Michel A. Steiner, et al.
ChemMedChem (2014) Vol. 9, Iss. 11, pp. 2486-2496
Closed Access | Times Cited: 38
Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
Michael A. Letavic, Pascal Bonaventure, Nicholas I. Carruthers, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 14, pp. 5620-5636
Closed Access | Times Cited: 38
Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor
David A. Perrey, Nadezhda German, Brian P. Gilmour, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 17, pp. 6901-6916
Open Access | Times Cited: 37
Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus
Alessandra Matzeu, Rémi Martin‐Fardon
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 35
Recent Advances in Multicomponent Reaction Chemistry
Christopher Hulme, Muhammad Ayaz, Guillermo Martinez‐Ariza, et al.
(2015), pp. 145-187
Closed Access | Times Cited: 33
Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2
Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 9, pp. 1884-1891
Closed Access | Times Cited: 31
Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats
Alessandra Matzeu, Rémi Martin‐Fardon
Neuropharmacology (2019) Vol. 164, pp. 107906-107906
Open Access | Times Cited: 28
Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists
Tatsuhiko Fujimoto, Jun Kunitomo, Yoshihide Tomata, et al.
Bioorganic & Medicinal Chemistry Letters (2011) Vol. 21, Iss. 21, pp. 6414-6416
Closed Access | Times Cited: 27
Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor
Norihito Oi, Michiyuki Suzuki, Taro Terauchi, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 16, pp. 6371-6385
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top